Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE)

Research analysts at Cantor Fitzgerald started coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a note issued to investors on Wednesday, MarketBeat reports. The firm set an “overweight” rating on the stock.

Other equities analysts also recently issued research reports about the company. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Weiss Ratings assumed coverage on shares of Satellos Bioscience in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Satellos Bioscience presently has an average rating of “Hold”.

Satellos Bioscience Price Performance

MSLE opened at $8.56 on Wednesday. The stock has a market cap of $132.34 million, a PE ratio of -7.13 and a beta of 1.10. Satellos Bioscience has a fifty-two week low of $4.53 and a fifty-two week high of $13.39.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.